|
Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial
|
Mavoko, H. M.; Nabasumba, C.; da Luz, R. I.; Tinto, H.; D'Alessandro, U.; Kambugu, A.; Baraka, V.; Rosanas-Urgell, A.; Lutumba, P.; Van geertruyden, J. P.
|
Lancet Global Health |
2017
|
Article-E
|